Yahoo · Oct 16, 2026
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
HO
NASDAQ · HOWL
Werewolf Therapeutics, Inc.
Healthcare · Biotechnology
$1.07
Up+$0.02 (+1.90%)
Updated Nov 4, 2026, 3:30 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 53.38M
- P/E ratio
- -0.69
- Dividend yield
- 0.00%
- 52-week range
- $0.27 – $1.43
- Volume
- 251.61K
- Avg. volume
- 938.4K
Price performance · HOWL
HOWL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
HOWL closed at $1.07 after 21 trading sessions, up 16.28% for the selected period.
- Last close
- $1.07
- Period change
- +16.28%
- Period low
- $0.91
- Period high
- $1.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $1.04 | $1.08 | $1.03 | $1.07 | 251.61K |
| Nov 2, 2026 | $0.9862 | $1.06 | $0.9862 | $1.05 | 272.2K |
| Oct 30, 2026 | $1.09 | $1.09 | $0.97 | $0.9861 | 415.56K |
| Oct 29, 2026 | $1.08 | $1.10 | $1.0501 | $1.10 | 400.92K |
| Oct 28, 2026 | $1.03 | $1.08 | $1.02 | $1.06 | 388.96K |
| Oct 27, 2026 | $0.99 | $1.05 | $0.96 | $1.04 | 308.1K |
| Oct 26, 2026 | $0.99 | $0.9999 | $0.95 | $0.9806 | 477.48K |
| Oct 23, 2026 | $1.01 | $1.03 | $0.9801 | $0.9801 | 211.04K |
| Oct 22, 2026 | $1.01 | $1.05 | $1.00 | $1.01 | 184.16K |
| Oct 21, 2026 | $1.05 | $1.06 | $1.01 | $1.03 | 199.37K |
| Oct 20, 2026 | $1.03 | $1.09 | $1.03 | $1.05 | 485.74K |
| Oct 19, 2026 | $0.9792 | $1.055 | $0.9792 | $1.04 | 378.85K |
| Oct 16, 2026 | $1.01 | $1.01 | $0.9703 | $0.98 | 309.25K |
| Oct 15, 2026 | $0.9615 | $1.0176 | $0.9615 | $0.997 | 426.22K |
| Oct 14, 2026 | $0.99 | $1.025 | $0.9657 | $0.98 | 664.07K |
| Oct 13, 2026 | $1.00 | $1.0101 | $0.97 | $0.9911 | 355.21K |
| Oct 12, 2026 | $0.98 | $1.02 | $0.9601 | $0.9818 | 811.41K |
| Oct 9, 2026 | $0.93 | $0.99 | $0.9201 | $0.9796 | 704.63K |
| Oct 8, 2026 | $0.92 | $0.9281 | $0.907 | $0.91 | 631.37K |
| Oct 7, 2026 | $0.916 | $0.9246 | $0.9077 | $0.9201 | 381.62K |
| Oct 6, 2026 | $0.94 | $0.94 | $0.9101 | $0.9202 | 279.15K |
Latest HOWL news
The latest Smart Investors Daily articles mentioning HOWL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HOWL research
Overview
Company profile and research snapshot.
Company profile
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $12.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 18, 2025 | B of A Securities | Buy | — |
| Aug 25, 2025 | B of A Securities | Buy | — |
| Aug 21, 2025 | JMP Securities | Market Outperform | — |
| May 9, 2025 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 16, 2026
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
Yahoo · Oct 13, 2026
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Oct 13, 2026
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
